Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
19.32 -0.35 (-1.78%) 10:15 ET [NASDAQ]
18.99 x 100 19.72 x 100
Realtime by (Cboe BZX)
18.99 x 100 19.72 x 100
Realtime 18.90 -0.77 (-3.91%) 05:57 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
19.32
Day High
19.32
Open 19.32
Previous Close 19.67 19.67
Volume 1,044 1,044
Avg Vol 9,978 9,978
Stochastic %K 94.69% 94.69%
Weighted Alpha -10.49 -10.49
5-Day Change -0.04 (-0.21%) -0.04 (-0.21%)
52-Week Range 12.12 - 29.19 12.12 - 29.19
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,739
  • Shares Outstanding, K 3,190
  • Annual Sales, $ 1,020 K
  • Annual Income, $ -18,460 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.81
  • Price/Sales 61.78
  • Price/Cash Flow N/A
  • Price/Book 4.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.73
  • Number of Estimates 1
  • High Estimate -0.73
  • Low Estimate -0.73
  • Prior Year -1.17
  • Growth Rate Est. (year over year) +37.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.63 +32.06%
on 04/08/25
Period Open: 16.64
19.84 -2.62%
on 04/17/25
+2.68 (+16.11%)
since 03/21/25
3-Month
13.50 +43.11%
on 01/23/25
Period Open: 13.48
26.99 -28.42%
on 03/17/25
+5.84 (+43.32%)
since 01/22/25
52-Week
12.12 +59.40%
on 07/29/24
Period Open: 24.43
29.19 -33.81%
on 04/30/24
-5.11 (-20.93%)
since 04/22/24

Most Recent Stories

More News
VTv Therapeutics: Q4 Earnings Snapshot

VTv Therapeutics: Q4 Earnings Snapshot

VTVT : 19.32 (-1.78%)
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

VTVT : 19.32 (-1.78%)
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

VTVT : 19.32 (-1.78%)
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q3 Earnings Snapshot

VTv Therapeutics: Q3 Earnings Snapshot

VTVT : 19.32 (-1.78%)
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q2 Earnings Snapshot

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q1 Earnings Snapshot

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q4 Earnings Snapshot

VTv Therapeutics: Q4 Earnings Snapshot

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q3 Earnings Snapshot

VTv Therapeutics: Q3 Earnings Snapshot

VTVT : 19.32 (-1.78%)
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q2 Earnings Snapshot

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q1 Earnings Snapshot

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Promising Upsides on these Biotech Penny Stocks

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

GMDA : 0.0327 (-18.25%)
VTVT : 19.32 (-1.78%)
SABS : 1.4100 (-1.12%)

Business Summary

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical...

See More

Key Turning Points

3rd Resistance Point 20.06
2nd Resistance Point 19.90
1st Resistance Point 19.78
Last Price 19.32
1st Support Level 19.50
2nd Support Level 19.34
3rd Support Level 19.22

See More

52-Week High 29.19
Fibonacci 61.8% 22.67
Fibonacci 50% 20.66
Last Price 19.32
Fibonacci 38.2% 18.64
52-Week Low 12.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro